A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC)
Phase of Trial: Phase I/II
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 24 Dec 2018 Planned primary completion date changed from 11 Dec 2018 to 11 Mar 2019.
- 01 Nov 2018 Planned primary completion date changed from 11 Oct 2018 to 11 Dec 2018.
- 15 Sep 2017 Status changed from not yet recruiting to recruiting.